Global Scopolamine Market Key Insights
During the forecast period of 2023-2035, the global scopolamine market is expected to reach an estimated value of ~USD 830 billion by 2035, by expanding at a CAGR of ~5%. The market further generated a revenue of ~USD 462 billion in the year 2022. Major key factors propelling the growth of scopolamine market worldwide are the proliferating investment in the pharmaceutical sector for the development of neurotherapeutics drugs that can contribute to the prevention of nausea and vomiting caused by recovery from anesthesia and surgery along with the surging number of surgeries worldwide.

Market Definition of Scopolamine
Scopolamine, with chemical formula C17H21NO4, is a poisonous alkaloid which is used for its anticholinergic effects. The drug is used to prevent nausea and vomiting caused by motion sickness or medications that are used during surgery. It is also used to treat certain stomach or intestinal problems, muscle spasms, and Parkinson-like conditions. Scopolamine works by blocking the effects of a certain natural substance known as acetylcholine on the central nervous system and it falls in a class of medications called antimuscarinics.
Get a Sample PDF Brochure: https://www.researchnester.com/sample-request-3312
Global Scopolamine Market: Growth Drivers
The growth of the global scopolamine market can majorly be attributed to the number of people suffering from mental disorders such as anxiety and depression with the rising use of scopolamine as an antidepressant and antianxiety drug. According to the Anxiety and Depression Association of America, anxiety disorders affect 40 million adults in the United States, or 18.1% of the population every year, and are the most common mental illness in the country. On the other hand, the market growth can also be attributed to the increasing number of travelers where around 1 in 3 people are considered highly susceptible to motion sickness along with the growing demand for medication used to manage motion sickness which is also projected to drive the market growth.
The global scopolamine market is also estimated to grow majorly on account of the following:
• Rising investment in the healthcare sector
• Increasing burden of diseases along with growing demand for antianxiety drugs owing to rising stress
• Rising prevalence of the musculoskeletal disorder
• Growing number of surgical interventions globally

Global Scopolamine Market: Restraining Factor
There are various severe side effects as well as withdrawal symptoms associated with the usage of scopolamine. Additionally, the prolonged use of transdermal scopolamine can lead to drug-dependent addiction. Hence, this factor is expected to be the major hindrance to the growth of the global scopolamine market during the forecast period.
Request for customization @ https://www.researchnester.com/customized-reports-3312
Global Scopolamine Market Segmentation
• By Dosage Form (Tablet, Syrup, Injection, Patch, and Others)
The patch segment, amongst all the other segments, is anticipated to garner the largest revenue by the end of 2035. Nowadays, scopolamine patches are widely adopted to treat nausea and vomiting post-surgery. These patches are highly preferred owing to their cost-effectiveness, rising availability, and ease of use. With the surge in the number of major surgeries that are performed each year reaching nearly 310 million, the segment for patches is projected to garner the largest share over the forecast period.
• By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
• By Region
The North America scopolamine market is anticipated to hold the largest market share by the end of 2035 among the market in all the other regions. The major factor anticipated to drive the growth of the market in North America during the forecast period is the rising demand for medication used to manage motion sickness in the region owing to the surge in traveling instances and the number of travelers in the region. For instance, domestic travel in the U.S. increased by 1.9% in 2018, which is a total of 2.3 billion-person trips, as per the reports of the U.S. Travel Association.

The market research report on global scopolamine also includes the market size, market revenue, Y-o-Y growth, and key player analysis applicable for the market in North America (U.S., and Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), and Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa).


Key Market Players Featured in the Global Scopolamine Market
Some of the key players of the global scopolamine market are Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co. Ltd., Alchem International Pvt. Ltd., Caleb Pharmaceuticals, Inc., GlaxoSmithKline plc, Phytex Australia, Fine Chemicals Corporation, Perrigo Company plc, Novartis International AGand others.
Obtain this Report @ https://www.researchnester.com/reports/scopolamine-market/3312

About Research Nester
Research Nester, which is a leading service provider for strategic market research and consulting services, aims to provide unbiased, unparalleled market insights and industry analysis. These analyses help conglomerates, executives, and industries to take wise decisions for their businesses as well as for their future marketing strategy, expansion and investment among others. We believe that our expertise in the field of market research can help businesses to expand to its new horizon. Our team of research analysts can provide businesses a right guidance at the right time, while our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.
Contact for more Info:
AJ Daniel
Email: [email protected]
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919